Group items tagged

Tough times for community pharmacies in England are far from over as the industry continues to grapple with major gaps in the workforce. Even though the latest figures released by the Health Education England (HEE) Community Pharmacy Workforce Survey 2021 showed doubling of pharmacist vacancy rate in England to 8 per cent between 2017 and 2021, it flagged the contractors' difficulty level in filling up these positions. The survey report showcased changes in the size and make-up of the community pharmacy workforce since the last survey conducted in 2017. It revealed that 56 per cent of pharmacy contractors reported high difficulty level in recruiting pharmacists, up from 21 per cent in the earlier survey. Moreover, a greater proportion - 60 per cent of contractors found filling up the pharmacy technician role 'fairly' or 'very' difficult. Other roles in the sector considered difficult to fill included accuracy checkers and trained dispensing assistants, both at 58 per cent.

RPS Scotland has named Fiona McIntyre as its new Policy and Practice Lead. With a background in hospital pharmacy, McIntyre will be responsible for policy development and professional support at RPS Scotland, and is set to assume her new role in early October. McIntyre will assume a leadership role for specific projects across Great Britain, collaborating with the Policy and Practice Leads in England and Wales, RPS Scotland said in a statement. Her responsibilities include representing pharmacists in working groups and meetings, engaging with pharmacists and pharmacy organisations, and supporting the RPS Director for Scotland. "During my career in NHS Scotland, I have advocated for pharmacy teams whenever possible," said McIntyre. "I am passionate about the profession's role in the safe and effective use of medicines, and I'm privileged to join the RPS. I look forward to promoting pharmacy in Scotland and helping our profession reach its full potential." "I'm pleased that Fiona will be joining the RPS Scotland team as our policy lead," said Laura Wilson, Director for RPS Scotland. "Fiona's experience will be invaluable to the role, and the whole team looks forward to her starting with us in October."

Pharmanovia, a global pharmaceutical company has announced increased targets to divert 40 per cent of its air shipments to sea in 2023, and 75 per cent by the end of 2028. It has made the pledge as it revealed the significant progress made towards achieving its ambitious science-backed ESG initiatives in its new Sustainability Report. Its industry-leading air-to-sea pilot scheme, which focused on its Spain-to-Australia freight route, cut an estimated 470,000kg in potential CO2 emissions in 2022 - reducing Scope 3 upstream transport emissions by 18 per cent. This initiative demonstrates Pharmanovia's role as an industry leader on carbon reduction and follows a recent report which stated just 16 of 500 pharmaceutical companies measured their entire Scope 3 emissions. The new Sustainability Report reveals that the Scope 2 emissions decreasing by 13 per cent in 2022, due to lower direct electricity demand within the office space. The company's packaging audit seeing a 52 per cent increase in the percentage of products packed with at least one fully recyclable component, up from 12% in 2021 to 64 per cent in 2022 Strong progress in an initiative which saw Pharmanovia set ESG goals all employees across its global offices as part of annual performance awards. Employees achieved a 98 per cent completion rate of the compliance training, including ESG modules

Sun Pharma has announced that it will acquire all outstanding shares of Concert Pharmaceuticals through a tender offer for an upfront payment of $8.00 per share of common stock in cash, or $576 million in equity value. The upfront payment of $8.00 per share of common stock in cash represents a premium of approximately 33% to Concert's 30-day volume weighted average price as of January 18, 2023, the last trading day prior to today's announcement. Concert is a late-stage biotechnology company pioneering the use of deuterium in medicinal chemistry. Concert has an extensive patent portfolio, including its lead product candidate deuruxolitinib - an oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of Alopecia Areata, an autoimmune dermatological disease - which is in late-stage development. It has completed the evaluation of the efficacy and safety of deuruxolitinib in adult patients with moderate to severe Alopecia Areata in its THRIVE-AA Phase 3 clinical program and two open label, long-term extension studies are ongoing in North America and Europe. Sun Pharma's immediate focus would be to follow Concert's plan to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the first half of 2023.

Perrigo, one of the world's largest providers of self-care products has appointed Ronald van Workum as Sales Director Germany, Customer Strategy & Implementation DACH Cluster. van Workum will continue to drive the successful integration of HRA Pharma into the Perrigo network, with a focus on well-known brands such as Abtei, Compeed and Granu Fink. He most recently held the position of Head of Key Account Management for Perrigo in Europe, based in the Netherlands. Prior to joining Perrigo he worked for Procter & Gamble in several countries, including Singapore, and in various functions, including: Market Strategy Planning Manager for the Gillette brand; and in Europe as multifunctional Team Leader Emerging Channels. The company also announced Tobias Geiger has been promoted from his role as Finance Director of the Perrigo DACH Cluster, which he held since April 2020, to General Manager of the Perrigo DACH Cluster. During this time, he successfully supported the implementation and stabilisation of the DACH cluster. He also led several business optimisations with his teams, such as the implementation of SAP in Switzerland, process digitalisation and the creation of a DACH Finance Business Partner Model. Before joining Perrigo, Geiger worked for Sanofi for more than 10 years in various leadership positions in DACH and in Latin America.

People who use pharmacies in parts of Pendle have suffered shortages or delays in buying prescription medicines such as insulin, councillors have been told. In the Barnoldswick area, a number of pharmacies have been impacted and some councillors hope a new regional NHS organisation might look into the problems. However, pharmacies in the neighbouring town of Nelson are facing shortages with other medicines. A pharmacists in Nelson Pharmacy told Pharmacy Business that he was struggling to meet local demand for children's paracetamol due to ongoing shortages. Pendle Council's West Craven Area Committee heard about the issues at its latest local meeting, held in Earby. An agenda for the committee stated: "Pharmacy provision in West Craven. It is reported that there is an acute problem with people being unable to get prescriptions filled, with Whitworth chemists suffering a breakdown in service. Previously, Well chemists has suffered similar problems." Speaking at the meeting, Lib-Dem Coun David Whipp said: "It's quite an appalling situation where people are queuing 30 minutes to get a prescription filled but when they get to the counter they are told it's not ready. They have to go home and come back at 5pm. It's an ongoing problem. "It includes insulin, which is critical for people with diabetes. I know several people who have failed to get insulin, It's a very serious problem." He added: "I think the committee should contact the local integrated care service. I think they are responsible for primary care which includes pharmacies. We need to find out what's happening and improve things in future. "

In the UK, many people with nonoptimal diets are at risk of nutrient deficiencies, as they receive less than the recommended intakes of several key vitamins and minerals, which can impact overall health. Dietary supplements can be one method of treating a deficiency. Dietary supplements like vitamins, antioxidants, fibre, and amino acids are sold in pharmacies across the world, and it is estimated that half of UK adults use at least one dietary supplement per day. Combined with an increased popularity in vegetarian, pescatarian, vegan and flexitarian diets, there's a chance patients are not consuming enough vital vitamins and minerals. If you think a patient's diet may be lacking in some of the important nutrients our bodies need to function properly, the advice below will provide more information about five of the most common nutrient deficiencies, and where to find these nutrients from easily accessible and plant based sources. 1. Omega-3 Essential fatty acids come in two forms; docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), and are both sources of energy and play key roles in the development of cell membrane structures. They also play a role in protecting against a variety of diseases and regulating blood pressure and inflammation. DHA is an important component of neurons and healthy nervous systems. Traditionally, seafood, red meat and dairy products have been touted as the main dietary sources of EPA and DHA. Although EPA and DHA can be difficult to source from plant based foods, ALA - the most common fatty acid - is found in plant based foods and can be converted into long chain omega-3s EPA and DHA.

The number of pharmacists working in community pharmacy in England has increased by 19 per cent in five years, according to new data released by the Department of Health and Social Care (DHSC). As of 31 October 2022, there were 27,711 community pharmacists in the country, as compared to 23,284 in 2017, an increase of almost 4,500. Pharmacy minister Andrea Leadsom revealed these figures yesterday (14 December) while responding to a written question from Karin Smyth, Shadow Minister of Health, in the parliament. Smyth asked - how many and what proportion of community pharmacists have worked in England for each of the last 10 years.

Monkeypox appears to be spreading from person to person in England, the UK Health Security Agency (UKHSA) said on Wednesday (June 1). The usually mild viral disease, which is endemic in west and central Africa, is understood to spread through close contact. Until early May, cases rarely cropped up outside Africa and were typically linked to travel to there. "The current outbreak is the first time that the virus has been passed from person to person in England where travel links to an endemic country have not been identified," the agency said. According to the UKHSA, the majority of cases in the United Kingdom - 132 - are in London, while 111 cases are known to be in gay, bisexual, or other men who have sex with men. Only two cases are in women. Recent foreign travel to a number of different countries in Europe within 21 days of symptom onset has been reported by 34 confirmed cases, or about 18 per cent of the 190 cases of the disease that have been confirmed by the United Kingdom as of May 31.

The Joint Committee on Vaccination and Immunisation (JCVI) on Thursday (May 19) said that an anticipated autumn Covid booster campaign would be aimed at people aged over 65, care home residents, frontline health and social care workers and all adults in a clinical risk group. The UK is offering a spring booster to the over-75s, care home residents and immunosuppressed people, and ministers have spoken openly of plans for a further booster campaign in the autumn. In interim advice, the JCVI stopped short of recommending another shot for all adults, though said the advice would be reviewed and updated. "The JCVI's current view is that in autumn 2022, a Covid-19 vaccine should be offered to: residents in a care home for older adults and staff; frontline health and social care workers; all those 65 years of age and over; and adults aged 16 to 64 years who are in a clinical risk group," the UK Health Security Agency said in a statement. Prime minister Boris Johnson, who was fiercely criticised for his handling of the early stages of the pandemic, lifted Covid restrictions in England in February, crediting Britain's quick initial vaccine rollout and the rollout of boosters with breaking the link between cases and deaths.

Patient safety should remain a top priority in any healthcare setting. People should always receive the right advice, and pharmacists aren't 'GPs on the cheap.' Staff should be fully trained, and medical equipment should be correctly maintained at all times. In turn, this helps create a safer environment for patients and professionals alike. In this article, we'll discuss some of the factors that can enhance patient safety in healthcare settings. AUTOMATION AND MONITORING Automating processes within a facility can help streamline operations. This has the potential to reduce or eliminate human error that could result in serious injury or death. In addition, automated systems often provide instant alerts when something goes wrong - allowing medical staff to react quickly and appropriately. Automated solutions can help facilities achieve hand hygiene monitoring standards, and it's possible to schedule a demo and see their outcomes. They can reduce staff sick time and HAIs, as well as Joint Commission citations and associated costs. Monitoring helps ensure compliance with safety protocols. It's essential for improving patient safety and gaining data on all aspects of a facility's operations. It also helps organizations track the effectiveness of their protocols and procedures over time. This helps them constantly evaluate and refine their policies, to maximize patient safety benefits. ADEQUATE STAFFING In order to provide quality care, it's essential to have enough staff on hand to meet patient needs and ensure all protocols are being followed. Without this, healthcare providers may struggle to provide prompt, efficient care - which can put patient safety at risk. Adequate staffing levels should be determined by a variety of factors. They include patient numbers, the complexity of care required, and the size and layout of the facility.

Proper drug storage is essential to ensure the safety of yourself, your family, and those around you. This is especially important if you are taking multiple medications and need to keep track of them all. Knowing how to store drugs correctly can help prevent misuse or accidental ingestion by children or pets. Here are six important guidelines about proper drug storage that everyone should follow: 1. KEEP ALL MEDICATIONS IN THEIR ORIGINAL, LABELED CONTAINERS: Using alternative storage containers can make it difficult to identify medications or keep track of expiration dates. Keeping medications in their original containers also prevents accidental misuse and helps ensure that the correct dosage is taken. In addition, it's important to store all medications out of reach of children and pets. Also, keep medications in a cool, dry place away from direct sunlight. For example, a medicine cabinet in the bathroom or kitchen is a good option. 2. DISPOSE OF EXPIRED MEDICATIONS: Expired medications can be less effective and even potentially harmful if taken, so it's important to regularly check expiration dates and get rid of any outdated medications. The best way to dispose of old drugs is to take them to a drug collection site. If no such sites are available, mix the medication with something like coffee grounds, put it in an opaque container, and then throw it away in your trash bin. Never flush expired medication down the toilet unless instructed by your pharmacist or healthcare provider! 3. STORE DRUGS IN A COOL, DRY PLACE: Extreme temperatures can cause medications to break down and become ineffective. To avoid this, keep all drugs away from direct sunlight, heat sources, and moisture. A medicine cabinet or drawer in the bathroom is an ideal spot for storing most drugs, but some require special storage conditions (more on that below). Different medications should also be separated from one another to avoid confusion and stored differently. For example, if a

Community pharmacies must be involved in future planning for public health emergencies, especially in cases where a quick response is needed such as the Covid-19 pandemic, a European-wide research has recommended. The project, co-led by the University of Huddersfield professor Zaheer-Ud-Din Babar in medicines and healthcare, focuses on how community pharmacies dealt with the pandemic, covering 31 pharmacy interventions on Covid-19 in 32 countries in Europe. The interventions include prevention, response, and recovery measures. It also covers improved access to medicines, expanded powers granted to pharmacies, rapid antigen testing, along with Covid-19 vaccination. Community pharmacists in the US, Canada, and Australia have been engaged in pandemic prevention, preparedness, and response strategic guidance after the 2009 flu pandemic. The aim of the research is to map the current reported practice and trends and review the pharmacies' intervention in Europe.

Deaths caused by hepatitis C has declined by 35 per cent in England between 2015 and 2020, latest data from the UK Health Security Agency (UKHSA) revealed. It showed that estimated prevalence of chronic hepatitis C in England has continued to fall to around 81,000 in 2020 from 129,000 in 2015, showing a considerable progress has been made towards eliminating the virus as a public health problem by 2030 in England. Commenting on the data release, health and social care secretary Sajid Javid, said: "It is fantastic to see the significant progress that has been made in eliminating hepatitis C in England. Deaths and prevalence of the virus have fallen consistently thanks to improvements in diagnosis, access to treatments and the hard work of the NHS. "This is another example of the UK being at the forefront of tackling serious diseases. We are on track to eliminate this virus by 2030 and I urge anyone who may be at risk to get tested as soon as possible."

Boots witnessed a 'record-breaking' performance for beauty driving retail sales with a growth of 16 per cent in the three months to 28 February 2023. The beauty category delivered a record January, and premium beauty saw its biggest ever sales week in December. Skincare reported three consecutive weeks of record sales in December driven by the 'expert skincare' category in which brands including No7, La Roche-Posay, CeraVe and Eucerin proved popular. Boots beauty transformation strategy continued with 19 new beauty halls opened in Q2 and the 170th store to receive a beauty makeover opening at Westfield White City post-period end. Boots now stocks over 500 big name and cult beauty brands and exclusively sells the UK's leading skincare brand, No7. The business reported its eighth consecutive quarter of market share growth with gains across all categories, led by beauty - the stand-out performer of the quarter. Footfall, basket size and the number of Advantage Card customers all increased, as more people chose to shop at Boots. The Christmas period was particularly strong with retail sales in the five weeks to 31 December up 17.4% and outperforming the market. Boots further expanded its value offering in the quarter, announcing its biggest ever savings as part of its continued focus on the affordability of life's essentials. This included the addition of 60 new products to the Boots Everyday label as well as the extension of its Price Advantage scheme, which has to date resulted in £30 million of customer savings and now includes discounts on over 800 products every month.

Early detection and treatment of Alzheimer's disease require the use of dependable and cost-effective screening technologies. Researchers at Sweden's Karolinska Institutet have revealed that the level of tau, a protein that plays a vital role in the development of severe dementia, is associated with a kind of sugar molecule in the blood. The study, which is published in Alzheimer's & Dementia, can pave the way for a simple screening procedure able to predict onset ten years in advance. "The role of glycans, structures made up of sugar molecules, is a relatively unexplored field in dementia research," says the study's first author Robin Zhou, medical student and affiliated researcher at the Department of Neurobiology, Care Sciences and Society (NVS), Karolinska Institutet. "We demonstrate in our study that blood levels of glycans are altered early during the development of the disease. This could mean that we'll be able to predict the risk of Alzheimer's disease with only a blood test and a memory test." In Alzheimer's disease, the neurons of the brain die, which is thought to be a result of the abnormal accumulation of the proteins amyloid beta and tau. Clinical trials for Alzheimer's drugs show that treatment should commence early in the pathological process, before too many neurons have died, to reverse the process before it is too late.

"We need to fix the front door to our NHS by investing in community pharmacy," asserts Daisy Cooper as more and more pharmacies "worry about the future of their business." Reflecting on the challenges faced by pharmacists during the pandemic, she emphasised their pivotal role in launching vaccination schemes across communities and the larger role pharmacies play in complementing traditional NHS facilities. Cooper recalls her collaboration with local pharmacies in St. Albans, where she worked hand in glove with them to address challenges faced by pharmacists to obtain information from NHS England regarding protocols and procedures. She told Pharmacy Business reporter that she had to work out something "hand in glove to help them get those vaccinated schemes up and running, as pharmacies were desperate to take part in the vaccination scheme" in her constituency. Describing their unique selling point (USP), Cooper emphasised the convenience and immediacy of pharmacies located in high street areas and warned that pharmacy closures "should be a real wake up call for the government."

In 2023, almost 14,000 people in England are estimated to have died due to excessive waits in emergency departments, averaging more than 260 deaths per week, according to new figures from the Royal College of Emergency Medicine (RCEM). The RCEM estimate is based on a large study of NHS patients published in the Emergency Medicine Journal in 2021, which found one excess death for every 72 patients who spent eight to 12 hours in an A&E department. Following a Freedom of Information audit of NHS trusts, the college has found that 65 per cent of people waiting 12 hours or more in A&E were patients waiting for a hospital bed. NHS data for England revealed that over 1.5 million patients waited 12 hours or more in major emergency departments last year. Based on the RCEM calculation, this indicates that over a million of those patients were waiting for a bed.

In a significant move aimed at improving patient care and alleviating hospital pressures, the National Health Services (NHS) has expanded its same day emergency care services across the UK. This has resulted in thousands more individuals receiving rapid tests and treatment, effectively avoiding overnight hospital stays. Recent data paints a promising picture, revealing an 11 per cent increase in the number of patients discharged on the same day they were admitted as emergencies. This advancement translates to several patients receiving urgent care within hours, subsequently freeing up beds for others in need. Over the past year alone, an impressive 206,446 more patients have been discharged on the same day, amounting to 2,024,129 individuals in the year leading up to January 2024, compared to 1,817,683 in the preceding year. The successful rollout of same day emergency care to every hospital in England has played a pivotal role in easing bed congestion and reducing hospital admissions by up to 30 per cent in certain NHS Trusts.

Boots and the Pharmacists' Defence Association (PDA) Union have released a joint statement to confirm that there will be a pay increase for trainee pharmacists in England and Northern Ireland from April 2024. From 1 April 2024, the new hourly pay rate for trainee pharmacists working at Boots pharmacies will be £12.69 for Zone A in England/Northern Ireland, £13.79 for Zone B in England and £14.05 for Zone C in England. "This increase will be applied centrally in the April pay run," said the statement from the Boots and the PDA Union. Team members can see the new rate of pay in the Benefits Box during the annual enrolment window from 20 February 2024, it added. In August 2023, pay for trainee pharmacists at Boots in England and Northern Ireland was increased to £11.64 per hour for Zone A, £12.77 per hour for Zone B and £12.88 per hour for Zone C.